Dermatológia pre prax 4/2024

Ixekizumab in the therapy of palmoplantar psoriasis – case report

Introduction: Palmoplantar psoriasis is a chronic relapsing skin disease with a negative impact on patients quality of life. Palmoplantar psoriasis refers to a localized variant of psoriasis. The disease can be associated with many clinical forms, including predominantly thick scaly, hyperkeratotic plaques, or pustular lesions. Treatment of palmoplantar psoriasis is complicated, usually without sufficient efficacy. Case report: We report a case of a 62-year-old patient with palmoplantar psoriasis who achieved complete remission of the disease with ixekizumab treatment. The achieved treatment effect has currently persisted for 26 months. Conclusion: The monoclonal antibodies are required for adequate maintenance of clinical response or remission. Ixekizumab, an anti- IL-17A monoclonal antibody primarily indicated for the treat- ment of chronic plaque psoriasis, has also shown efficacy in the treatment of hard-to-treat areas, including palmoplantar psoriasis.

Keywords: palmoplantar psoriasis, monoclonal antibodies, biologics, ixekizumab, anti-IL-17A